Immunic Inc (IMUX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.11+2.74%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMUX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -30.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IMUX — litigation filed
Dated 2026-07-14
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth therein. Cautionary Note Regarding Forward-Looking Statements Certain statemen…
Why it matters: If health care sector revenue growth speeds up, it may help Immunic's performance. It could signal a better environment for the company.
Supportive ifHealth care sector revenue growth returns to near 10 percent or higher.
Worry ifHealth care sector revenue growth continues to slow or stays below 10 percent.
Why it matters: Better EPS means the company is managing costs well and is financially healthy. This affects how investors feel.
Supportive ifQ2 EPS results show a loss less than -$1.08.
Worry ifQ2 EPS results show a loss worse than -$1.08.
Why it matters: This data will show how well vidofludimus calcium works for relapsing MS. Positive results could boost confidence in the drug's potential.
Supportive ifData from the Phase 3 ENSURE trial shows strong results for relapsing MS.
Worry ifData shows no strong results or safety problems. This raises doubts about the drug.
Why it matters: Starting this program would grow the market for vidofludimus calcium.
Supportive ifThe Phase 3 program for progressive MS has been announced.
Worry ifNo announcement of the Phase 3 program initiation by the end of 2026.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$242 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $688 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,785 loss on $10,000 · 47.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Raising money is important for running the business and growing. It shows that investors believe in the company.
Supportive ifThey announced a successful private placement that raised at least $200M.
Worry ifNo progress or announcement of the capital raise by the next earnings call.
Why it matters: Raising money is important for funding trials and operations. It affects financial health.
Supportive ifCompletion of the capital raise with at least $400 million secured.
Worry ifFailure to secure the planned capital raise, leading to funding concerns.
Why it matters: This data will show how well vidofludimus calcium works for relapsing MS. It is crucial for the company's future.
Supportive ifThe Phase 3 ENSURE trials show good results for vidofludimus calcium.
Worry ifThe data shows no strong results for vidofludimus calcium in relapsing MS.